Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Antiviral medication has emerged as an important tool in the prevention of HIV infection. In this randomized, controlled trial, an injectable long-acting agent, cabotegravir, was found to be superior to daily oral tenofovir disoproxil fumarate–emtricitabine in preventing incident HIV infection in ci...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The New England journal of medicine Ročník 385; číslo 7; s. 595 - 608
Hlavní autori: Landovitz, Raphael J, Donnell, Deborah, Clement, Meredith E, Hanscom, Brett, Cottle, Leslie, Coelho, Lara, Cabello, Robinson, Chariyalertsak, Suwat, Dunne, Eileen F, Frank, Ian, Gallardo-Cartagena, Jorge A, Gaur, Aditya H, Gonzales, Pedro, Tran, Ha V, Hinojosa, Juan C, Kallas, Esper G, Kelley, Colleen F, Losso, Marcelo H, Madruga, J. Valdez, Middelkoop, Keren, Phanuphak, Nittaya, Santos, Breno, Sued, Omar, Valencia Huamaní, Javier, Overton, Edgar T, Swaminathan, Shobha, del Rio, Carlos, Gulick, Roy M, Richardson, Paul, Sullivan, Philip, Piwowar-Manning, Estelle, Marzinke, Mark, Hendrix, Craig, Li, Maoji, Wang, Zhe, Marrazzo, Jeanne, Daar, Eric, Asmelash, Aida, Brown, Todd T, Anderson, Peter, Eshleman, Susan H, Bryan, Marcus, Blanchette, Cheryl, Lucas, Jonathan, Psaros, Christina, Safren, Steven, Sugarman, Jeremy, Scott, Hyman, Eron, Joseph J, Fields, Sheldon D, Sista, Nirupama D, Gomez-Feliciano, Kailazarid, Jennings, Andrea, Kofron, Ryan M, Holtz, Timothy H, Shin, Katherine, Rooney, James F, Smith, Kimberly Y, Spreen, William, Margolis, David, Rinehart, Alex, Adeyeye, Adeola, Cohen, Myron S, McCauley, Marybeth, Grinsztejn, Beatriz
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Massachusetts Medical Society 12.08.2021
Predmet:
ISSN:0028-4793, 1533-4406, 1533-4406
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Antiviral medication has emerged as an important tool in the prevention of HIV infection. In this randomized, controlled trial, an injectable long-acting agent, cabotegravir, was found to be superior to daily oral tenofovir disoproxil fumarate–emtricitabine in preventing incident HIV infection in cisgender men and transgender women who have sex with men.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2101016